Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a promising biotechnology company with a strong focus on developing life-changing therapeutics for severe autoimmune and inflammatory disorders. Their drug candidate, EQ504, has shown promising results in pre-clinical studies and is targeting a high-demand market with few effective treatment options currently available. While the company may face funding challenges in the future, its potential for collaboration and expansion into other markets makes it a positive long-term investment opportunity.

Bears say

Equillium is a well-funded company with two promising drugs, obefazimod and EQ504, in its pipeline for treating severe autoimmune and inflammatory disorders. While concerns about potential side effects may have caused a drop in stock prices, the successful Phase 3 trial of obefazimod supports the potential efficacy of EQ504, leading to potential high peak sales. However, as a clinical-stage biotech company, there are inherent risks to investing in Equillium's stock.

Equillium Inc (EQ) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.